Not necessarily, because Medicare already covers cancer treatment: Part A pays for inpatient care, Part B pays 80% of outpatient chemotherapy and radiation after the $283 deductible, and your Part D drug costs are capped at $2,100 out of pocket in 2026. Whether a separate cancer or critical illness policy is worth adding comes down to one question: what is paying the other 20%, the hospital deductible, and the costs that are not medical at all?
If you hold a Medicare Supplement plan, most of that is already answered and a cancer policy is buying cash, not coverage. If you are on a Medicare Advantage plan or on Original Medicare with no supplement, the exposure is real and can be counted. Same product, two very different answers, and the sales pitch rarely asks which one applies to you.
What a cancer policy actually pays
A cancer policy is a supplemental plan. It pays a benefit to you when a covered diagnosis occurs. There are two common designs:
- Lump sum. One cash payment on a first diagnosis of a covered cancer, typically a round number you choose at purchase. You spend it on anything.
- Scheduled benefit. Set dollar amounts for specific events: a hospital admission, each chemotherapy or radiation session, a surgery, a transport to a treatment center. It pays per event, up to the policy’s limits.
A critical illness policy works the same way as the lump-sum design but with a longer trigger list, usually cancer plus heart attack and stroke, and sometimes organ failure, major organ transplant or coronary bypass.
Here is what these policies are not, and this is the part to hold onto:
- They are not health insurance and not a substitute for it. Federal regulators classify specified-disease and fixed indemnity coverage as “excepted benefits,” which means they sit outside the rules that apply to comprehensive coverage (CMS). They do not pay your oncologist. Medicare does.
- They are not part of Medicare. Nothing about them is government-issued, government-endorsed or required by Medicare.
- They are not standardized. Unlike Medigap, where Plan G means the same thing from every carrier, every cancer and critical illness policy defines its own triggers, exclusions, waiting periods and limits. Two policies with the same benefit amount can pay very differently.
What Medicare already pays for cancer treatment in 2026
Before deciding whether to add anything, look at what Original Medicare already does. Chemotherapy and radiation are covered under Part A when you are a hospital inpatient and under Part B when you are an outpatient, in a doctor’s office or at a freestanding clinic (Medicare.gov: chemotherapy, radiation therapy). Your share, in 2026 dollars (CMS):
| Treatment setting | What Medicare pays | What you pay in 2026 |
|---|---|---|
| Inpatient hospital stay (Part A) | The stay, after your deductible | $1,736 deductible per benefit period; $434 a day for days 61–90; $868 a day for lifetime reserve days |
| Outpatient chemo or radiation in a doctor’s office or freestanding clinic (Part B) | 80% of the Medicare-approved amount | $283 annual deductible, then 20% coinsurance |
| Outpatient chemo or radiation in a hospital outpatient department (Part B) | 80% of the Medicare-approved amount | 20% coinsurance, but the copayment for a single service will not exceed the inpatient deductible |
| Oral chemotherapy, anti-nausea and pain medications (Part D) | Plan cost-sharing applies | Capped at $2,100 out of pocket for the year |
Two of those lines do the real damage. The Part B 20% has no annual cap under Original Medicare alone, and a course of infusion therapy or daily radiation over months can run that coinsurance into five figures. The Part D line is new and it works in the other direction: since the drug benefit redesign, your out-of-pocket spending on covered Part D drugs stops at $2,100 for the calendar year (CMS), which matters enormously for anyone on an oral cancer drug.
Standard Part B also carries a premium of $202.90 a month in 2026, but that is the price of having Part B at all, not a treatment cost. Our Medicare cost estimator puts the full-year picture together, including any IRMAA surcharge.
The answer depends on which Medicare you have
This is the question a cancer policy quote should start with and usually skips.
| Your coverage | Your treatment exposure | What a cancer policy is really doing |
|---|---|---|
| Original Medicare only (no supplement) | The Part A deductible each benefit period and an uncapped 20% of every outpatient treatment | Filling a genuine, open-ended gap |
| Original Medicare + Medigap (e.g. Plan G or Plan N) | Part B coinsurance covered; Part A deductible covered on most letters; Part D drugs up to $2,100 | Providing cash for non-medical costs and the drug cap |
| Medicare Advantage | Plan copays or coinsurance for each service until you reach the plan’s yearly out-of-pocket limit | Pre-funding part of the out-of-pocket limit with a known premium |
Original Medicare alone. This is the situation where the product has the strongest case. There is nothing sitting behind the 20%. That said, the more complete answer is usually a Medicare Supplement, because it covers every Part B service, not only cancer. If you are still inside your six-month Medigap open enrollment window, that decision comes first.
Medigap. Every standardized Medigap plan covers the Part B coinsurance, and most letters, including Plan G and Plan N, also cover the Part A deductible (Medicare.gov). Plan N adds copays of up to $20 for office visits and up to $50 for emergency room visits, and it does not cover Part B excess charges, which Florida permits. If you hold one of these, your share of Medicare-approved cancer treatment is already small. What remains is the $2,100 drug cap and everything that is not a medical bill. If you are still deciding between the two letters, our Plan G vs Plan N comparison shows where they differ.
Medicare Advantage. Advantage plans replace Original Medicare’s cost-sharing with their own copays and coinsurance for each service, and every plan sets a yearly limit on what you pay out of pocket for Part A and Part B services (Medicare.gov). Cancer treatment is exactly the kind of year that reaches that limit. Find the number in your plan’s Evidence of Coverage. A lump-sum policy is, in effect, a way of paying part of that limit in advance through a monthly premium. Whether the trade is worth it depends on the limit, the premium and your savings, and none of those three is a guess. The same logic applies to hospital indemnity insurance with Medicare, which we covered separately.
The costs Medicare does not pay, and never will
This is the honest argument for a cancer policy even when treatment is fully covered. A cancer diagnosis generates bills that are not medical and that no Medicare plan or Medigap letter touches:
- Travel and lodging. Treatment at a specialty center can mean a weekly drive or a stay near the hospital for weeks of daily radiation.
- A spouse’s lost income. A working spouse who becomes the driver and caregiver often cuts hours or stops.
- Help at home. Cooking, cleaning, yard work, transportation during the months you cannot do them.
- Deductibles on everything else. The Part B deductible, the Part D cap and Part A cost sharing still land in the same year.
A lump-sum benefit is designed for exactly these, because it is cash with no strings. Whether that is worth the premium is a household budget question, and it is a very different question from “am I covered.”
Cancer insurance vs critical illness insurance
People shopping one usually get offered the other. The difference is the trigger list.
| Cancer insurance | Critical illness insurance | |
|---|---|---|
| Pays on | A covered cancer diagnosis (and, in scheduled designs, specific treatments) | Any condition on the policy’s list: typically cancer, heart attack, stroke; often organ failure or transplant |
| Payment form | Lump sum, or scheduled amounts per treatment or event | Lump sum on diagnosis |
| Relative premium for the same benefit | Lower, one trigger | Higher, several triggers |
| Common reductions | Skin cancers and early-stage or in-situ cancers often excluded or paid at a reduced percentage | Same cancer reductions, plus strict definitions of “heart attack” and “stroke” |
| Who it tends to suit | Someone whose family history is specifically cancer | Someone who wants one policy for the three big diagnoses |
The case for the broader policy is in the numbers. About 38.9% of people will be diagnosed with cancer at some point in their lifetime, and an estimated 2,041,910 new cases were expected in the U.S. in 2025 (National Cancer Institute). Meanwhile, roughly 805,000 people in the U.S. have a heart attack each year, one every 40 seconds (CDC). A cancer-only policy leaves the second risk unaddressed. Whether that matters depends on your own history, and neither statistic is a prediction about you.
The Florida picture
Florida carries a heavier cancer load than the country as a whole. The state’s age-adjusted incidence rate is 467.6 new cases per 100,000 people per year, against a U.S. rate of 448.6, for 2018–2022 (NCI State Cancer Profiles). Part of that is simply age: Florida has a large retiree population, and cancer is largely a disease of later life. The mortality rate runs the other way, at 138.3 per 100,000 against 145.4 nationally for 2019–2023, which points to treatment access as much as anything.
That access has a Tampa address. Moffitt Cancer Center in Tampa is an NCI-designated Comprehensive Cancer Center, the highest designation the National Cancer Institute gives, and one of four NCI-designated centers in Florida alongside Mayo Clinic in Jacksonville, Sylvester in Miami and UF Health in Gainesville (NCI). For a family in Sarasota, Naples or St. Petersburg, that often means the treatment is in Tampa and the driving, parking and hotel nights are not. Those are precisely the costs a cash-benefit policy is built to cover, and precisely the costs Medicare is not.
There is also a network point for Advantage members. A comprehensive cancer center may or may not be in a given plan’s network, and out-of-network care on an HMO can mean paying the full cost. That is a plan-document question, checked before you need it, and it is a stronger reason to review your Advantage plan than to buy a supplemental policy.
Who a cancer or critical illness policy suits
It tends to make sense for:
- Advantage members with meaningful per-service copays and a yearly out-of-pocket limit they could not comfortably write a check for.
- People on Original Medicare with no supplement, as a stopgap, while recognizing that a Medigap plan addresses the same 20% for every condition.
- Households where a working spouse would lose income during a long treatment, or where distance to a treatment center is a real cost.
- Anyone with limited liquid savings who wants the first months of a diagnosis paid from a policy rather than a credit card.
It tends not to make sense for:
- Medigap holders with solid savings, whose treatment costs are already covered and who can absorb the drug cap and the travel.
- Anyone who would be relying on it as coverage. If a policy is being described to you as protection against the cost of cancer treatment, rather than as cash alongside coverage, that is the moment to stop and ask what Medicare already pays.
- Someone whose real worry is a long care need. A critical illness policy pays once, on diagnosis. It does not fund years of help with bathing and dressing after a stroke. That is a long-term care question, and our cost of care estimator prices it as the larger risk it is.
Six things to check before you buy
- The definition of each covered condition. “Cancer” in a policy usually excludes most skin cancers and may exclude or reduce benefits for carcinoma in situ or early-stage diagnoses. “Heart attack” and “stroke” have clinical definitions that some events will not meet.
- The waiting period. Many policies will not pay on a diagnosis in the first months after the policy starts. Some return the premium; some pay nothing.
- Pre-existing condition exclusions. A cancer treated in the years before the policy, or a related condition, may be excluded for a period or permanently.
- Benefit reductions by age. Some policies cut the benefit amount, sometimes by half, once you reach a stated age. If you are buying at 68, find out what the policy pays at 75.
- Whether it pays once or recurs. Some lump-sum policies pay a second, smaller benefit for a recurrence or a second unrelated diagnosis after a set interval. Some end after the first payment.
- What it costs relative to the gap. We do not print premium figures here because pricing turns on your age, the benefit amount, your health history, the carrier and your state, and a number in a blog post misleads more people than it helps. Get a real quote on the exact benefit amount, then set it against your plan’s actual out-of-pocket limit or your actual 20% exposure.
Underwriting, benefit amounts, definitions and availability all vary by carrier and by state. A policy sold in Florida may differ from the same carrier’s policy elsewhere, and any benefit or premium figure you see is an illustration until it is on a policy with your name on it.
The honest summary
Medicare pays for cancer treatment. A cancer or critical illness policy pays you, on a trigger, and hands you cash to spend on whatever the diagnosis costs beyond the medical bills. It is a narrow, legitimate tool, and it is neither the scare-story product some pitches make it nor the “complete protection” others promise.
If you are on Medigap, you are buying cash for the non-medical costs, so price it as that. If you are on Advantage or on Original Medicare alone, you have a countable gap, so count it, and consider whether a supplement closes it more completely. In every case, the policy sits alongside Medicare and never in place of it.
If you would like your own gap quantified before you decide, start with the Medicare cost estimator for the annual picture, then schedule a call. Virginia will go through your plan’s cost-sharing and out-of-pocket limit with you, line by line, and tell you whether a supplemental policy is solving a problem you actually have. There is nothing to buy on the first conversation.